FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2019-2020 November 4, 2004 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Wenzel, R. P. PubMed Citation

To the Editor: In his Perspective article (Aug. 5 issue),¹ Wenzel accurately describes the dismaying problem of the decreasing number of new antimicrobial drugs in the pharmaceutical pipeline. He notes that the Infectious Diseases Society of America (IDSA) has suggested extending the life of drug patents as an incentive to industry. Many other approaches need to be considered before making a radical change in a patent system designed to protect investment but eventually foster competition.

The IDSA has proposed a better idea. It recommends that the National Institutes of Health (NIH) remove roadblocks to antibiotic research and development and increase . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.